Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-24-041830
Filing Date
2024-10-02
Accepted
2024-10-02 12:09:07
Documents
3
Period of Report
2024-10-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1727885341.html 3  
1 FORM 3 wk-form3_1727885341.xml 3 4693
2 EX-24 sabatinibrent-section16p.htm EX-24 4248
3 sabatinibrent-section16p001.jpg GRAPHIC 210207
  Complete submission text file 0001628280-24-041830.txt   300033
Mailing Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158
Business Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Issuer) CIK: 0001706431 (see all company filings)

EIN.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O VIR BIOTECHNOLOGY, INC. 1800 OWENS STREET, SUITE 900 SAN FRANCISCO CA 94158
Business Address
Sabatini Brent (Reporting) CIK: 0002037272 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39083 | Film No.: 241345975